公开(公告)号：US20210252035A1

公开(公告)日：2021-08-19

申请号：US16897690

申请日：2020-06-10

Applicant: Epizyme, Inc.

Inventor： Edward J. OLHAVA ,  Richard CHESWORTH ,  Kevin W. KUNTZ ,  Victoria M. RICHON ,  Roy M. POLLOCK ,  Scott R. DAIGLE

IPC: A61K31/7076 ,  C07D487/04 ,  C07D473/34 ,  C07H19/14 ,  C07H19/16 ,  A61K31/519 ,  A61K31/52 ,  A61K31/7064

Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

公开(公告)号：US20180280422A1

公开(公告)日：2018-10-04

申请号：US15802979

申请日：2017-11-03

Applicant: Epizyme, Inc.

Inventor： Edward J. OLHAVA ,  Richard CHESWORTH ,  Kevin Wayne KUNTZ ,  Victoria M. RICHON ,  Roy M. POLLOCK ,  Scott R. DAIGLE

IPC: A61K31/7076 ,  C07H19/14 ,  C07D487/04 ,  C07H19/16 ,  A61K31/519 ,  A61K31/7064 ,  A61K31/52 ,  C07D473/34

Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

公开(公告)号：US20200009176A1

公开(公告)日：2020-01-09

申请号：US16415325

申请日：2019-05-17

Applicant: Epizyme, Inc.

Inventor： Roy M. POLLOCK ,  Scott R. DAIGLE ,  Eric HEDRICK ,  Nigel WATERS ,  Blythe THOMSON

IPC: A61K31/7076 ,  A61P35/02

Abstract: The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof

公开(公告)号：US20190076455A1

公开(公告)日：2019-03-14

申请号：US15533205

申请日：2015-12-04

Applicant: Epizyme, Inc.

Inventor： Roy M. POLLOCK ,  Scott R. DAIGLE ,  Eric HEDRICK ,  Nigel WATERS ,  Blythe THOMSON

IPC: A61K31/7076 ,  A61P35/02

Abstract: The present invention relates to a method for the treatment of leukemia and the induction of leukemic blast cell maturation or differentiation via the administration of the DOT1L inhibitor pinometostat (otherwise known as EPZ-5676; CAS Registry number 1380288-87-8) or its N-oxide or pharmaceutically acceptable salt thereof.